Evidence map›Paper›PMID 24374800›Full record

Trial reportJournal of cancer research and clinical oncology2014

Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial.

Minjie Yang, Zhuting Fang, Zhiping Yan, Jianjun Luo, Lingxiao Liu, Wen Zhang, Linlin Wu, Jingqin Ma, Qinghui Yang, Qingxin Liu

Erratum issued Registry-linked trialOpen access · greenAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02971345 (Endovascular Brachytherapy Combined With Stent Placement and Transcatheter Arterial Chemoembolization), which is not on this map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02971345 phase3unknown statusnot on this mapstarted 2017, after this paper: background citation

Endovascular Brachytherapy Combined With Stent Placement and Transcatheter Arterial Chemoembolization (TACE) for Treatment of HCC With Main Portal Vein Tumor Thrombus Versus TACE Alone: a Prospective Randomized Controlled Multicentre Trial

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2017 to 2020Enrolled253ConditionsHepatocellular Carcinoma, Portal Vein Tumor ThrombusArmsStent and Iodine-125 seed strand implantation, Stent, Iodine-125 seed, Epirubicin, Ultra-fluid lipiodol
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. [Expert consensus on precise diagnosis and management of primary hepatocellular carcinoma in advanced stage (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
  12. Article
  13. Review
  14. CT-guidedRadiology and oncology · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Development of a Novel Endovascular Brachytherapy Stent: A Proof-of-concept Study.Journal of clinical and translational hepatology · 2021
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Minjie YangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Zhuting Fang
Zhiping Yan
Jianjun Luo
Lingxiao Liu
Wen Zhang
Linlin Wu
Jingqin Ma
Qinghui Yang
Qingxin Liu
Fudan University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere was no standard treatment for hepatocellular carcinoma with portal vein tumour thrombosis (PVTT). This prospective, randomised, two-arm clinical trial aims to investigate the feasibility, safety and effectiveness of transarterial chemoembolisation (TACE) combined with the endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus conventional TACE. PATIENTS AND

methodsEighty-five patients who met the eligibility requirements were randomly assigned to receive the treatment of TACE combined with the endovascular implantation of an iodine-125 seed strand (43 cases) or conventional TACE (42 cases). The end points were survival time, complications related to the procedure and adverse events.

resultsNo significant differences in baseline characteristics were observed between groups. The mean and median survival times were 221.7 ± 16.3 days [95 % confidence interval (CI) 189.8-253.6 days] and 210.0 ± 17.5 days (95 % CI 175.8-244.2 days) in group A and 155.1 ± 7.9 days (95 % CI 139.6-170.5 days) and 154.0 ± 11.2 days (95 % CI 133.2-176.0 days) in group B (P = 0.000). The 90-, 180- and 360-day cumulative survival rates were 97.6, 58.9 and 12.3 % in group A and 92.5, 30.7 and 0 % in group B (P = 0.000).

conclusionTransarterial chemoembolisation combined with the endovascular implantation of an iodine-125 seed strand is feasible, safe and effective in the treatment for hepatocellular carcinoma with PVTT.

Indexed as

Blood Vessel Prosthesis ImplantationChemoembolization, TherapeuticPortal VeinCarcinoma, HepatocellularCombined Modality TherapyEndovascular ProceduresFeasibility StudiesFemaleFollow-Up StudiesHumansIodine RadioisotopesLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisIodine Radioisotopes

Identifiers

PMID24374800
PMCPMC11823926
OpenAlexW2067095091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.